Skip to content
The Nexus
DossierENTITY

Dr. Anna Lok

Coverage of Dr. Anna Lok in the Nexus archive.

Earliest in view: May 28 · 19:23 UTCMost recent: May 28 · 19:23 UTC
Co-mentioned in this coverage
bepirovirsentopic1GSKorganization1Ionis Pharmaceuticalsorganization1hepatitis Btopic1Dr. Seng Gee Limperson1U.S. Food and Drug Administrationorganization1New England Journal of Medicineorganization1
Recent coverage
  • HEALTHMay 28 · 19:23 UTCAP NEWS
    Experimental hepatitis B drug may offer ‘functional cure’ for some patients

    An experimental hepatitis B drug called bepirovirsen may offer a 'functional cure' for some patients, with 20% of trial participants maintaining undetectable virus levels after stopping treatment. Developed by GSK and Ionis Pharmaceuticals, the drug is under fast-track FDA review and shows potential to address chronic hepatitis B, which affects over 250 million people globally.

Dr. Anna Lok · Dossier · The Nexus